Compare ROIV & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROIV | GEHC |
|---|---|---|
| Founded | 2014 | 1892 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7B | 29.1B |
| IPO Year | 2021 | 2022 |
| Metric | ROIV | GEHC |
|---|---|---|
| Price | $35.43 | $65.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 21 |
| Target Price | $48.08 | ★ $82.90 |
| AVG Volume (30 Days) | ★ 6.0M | 3.3M |
| Earning Date | 11-09-2026 | 10-28-2026 |
| Dividend Yield | N/A | ★ 0.25% |
| EPS Growth | N/A | ★ 4.84 |
| EPS | N/A | ★ 0.85 |
| Revenue | $8,260,000.00 | ★ $20,625,000,000.00 |
| Revenue This Year | $530.75 | $5.33 |
| Revenue Next Year | $685.92 | $4.60 |
| P/E Ratio | ★ N/A | $75.55 |
| Revenue Growth | N/A | ★ 4.84 |
| 52 Week Low | $15.99 | $58.75 |
| 52 Week High | $42.50 | $89.77 |
| Indicator | ROIV | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | 43.66 | 47.88 |
| Support Level | $33.15 | $60.14 |
| Resistance Level | $35.70 | $66.04 |
| Average True Range (ATR) | 1.14 | 1.33 |
| MACD | -0.34 | 0.13 |
| Stochastic Oscillator | 35.90 | 60.90 |
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).